Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Infertility Therapeutics Market: By Drug Class, Biguanides, Others), By Route of Administration , By Gender, By Distribution Channels, and Geography Â
1. Executive Summary |
2. Global Infertility Therapeutics Market Introduction |
2.1. Global Infertility Therapeutics Market – Taxonomy |
2.2. Global Infertility Therapeutics Market –Definitions |
2.2.1. By Drug Class |
2.2.2. By Route of Administration |
2.2.3. By Gender |
2.2.4. By Distribution Channels |
2.2.5. By Region |
3. Global Infertility Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Infertility Therapeutics Market Dynamic Factors - Impact Analysis |
3.6. Global Infertility Therapeutics Market – Competition Landscape |
4. Global Infertility Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 |
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Infertility Therapeutics Market, By Drug Class, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.1. Gonadotropin |
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Aromatase Inhibitors |
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Selective Estrogen Receptor Modulators (SERMs) |
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Biguanides |
5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6. Global Infertility Therapeutics Market, By Route of Administration, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.1. Oral |
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Intravenous |
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Subcutaneous |
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Intramuscular |
6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Infertility Therapeutics Market, By Gender, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
7.1. Men |
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Women |
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Infertility Therapeutics Market, By Distribution Channels, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Infertility Therapeutics Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.1. North America |
9.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Infertility Therapeutics Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Gender, By Distribution Channels, and Region, 2022-2028 |
10. North America Infertility Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
10.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Gonadotropin |
10.1.2. Aromatase Inhibitors |
10.1.3. Selective Estrogen Receptor Modulators (SERMs) |
10.1.4. Biguanides |
10.1.5. Others |
10.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Oral |
10.2.2. Intravenous |
10.2.3. Subcutaneous |
10.2.4. Intramuscular |
10.3. Gender Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Men |
10.3.2. Women |
10.4. Distribution Channels Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacies |
10.4.2. Retail Pharmacies |
10.4.3. Online Pharmacies |
10.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. USA |
10.5.2. Canada |
10.6. North America Infertility Therapeutics Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Gender, By Distribution Channels, and Country, 2022-2028 |
10.7. North America Infertility Therapeutics Market Dynamics – Trends |
11. Europe Infertility Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
11.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Gonadotropin |
11.1.2. Aromatase Inhibitors |
11.1.3. Selective Estrogen Receptor Modulators (SERMs) |
11.1.4. Biguanides |
11.1.5. Others |
11.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Oral |
11.2.2. Intravenous |
11.2.3. Subcutaneous |
11.2.4. Intramuscular |
11.3. Gender Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Men |
11.3.2. Women |
11.4. Distribution Channels Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacies |
11.4.2. Retail Pharmacies |
11.4.3. Online Pharmacies |
11.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Spain |
11.5.5. Italy |
11.5.6. Russia |
11.5.7. Rest of Europe |
11.6. Europe Infertility Therapeutics Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Gender, By Distribution Channels, and Country, 2022-2028 |
11.7. Europe Infertility Therapeutics Market Dynamics – Trends |
12. Asia-Pacific Infertility Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
12.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Gonadotropin |
12.1.2. Aromatase Inhibitors |
12.1.3. Selective Estrogen Receptor Modulators (SERMs) |
12.1.4. Biguanides |
12.1.5. Others |
12.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Oral |
12.2.2. Intravenous |
12.2.3. Subcutaneous |
12.2.4. Intramuscular |
12.3. Gender Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Men |
12.3.2. Women |
12.4. Distribution Channels Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacies |
12.4.2. Retail Pharmacies |
12.4.3. Online Pharmacies |
12.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. China |
12.5.2. India |
12.5.3. Japan |
12.5.4. ASEAN |
12.5.5. Australia & New Zealand |
12.5.6. Rest of Asia-Pacific |
12.6. Asia-Pacific Infertility Therapeutics Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, by Drug Class, By Distribution Channels, and Country, 2022-2028 |
12.7. Asia-Pacific Infertility Therapeutics Market Dynamics – Trends |
13. Latin America Infertility Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
13.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Gonadotropin |
13.1.2. Aromatase Inhibitors |
13.1.3. Selective Estrogen Receptor Modulators (SERMs) |
13.1.4. Biguanides |
13.1.5. Others |
13.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Oral |
13.2.2. Intravenous |
13.2.3. Subcutaneous |
13.2.4. Intramuscular |
13.3. Gender Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Men |
13.3.2. Women |
13.4. Distribution Channels Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacies |
13.4.2. Retail Pharmacies |
13.4.3. Online Pharmacies |
13.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Mexico |
13.5.3. Rest of Latin America |
13.6. Latin America Infertility Therapeutics Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Gender, By Distribution Channels, and Country, 2022-2028 |
13.7. Latin America Infertility Therapeutics Market Dynamics – Trends |
14. Middle East and Africa Infertility Therapeutics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, US$ Mn) |
14.1. Drug Class Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
14.1.1. Gonadotropin |
14.1.2. Aromatase Inhibitors |
14.1.3. Selective Estrogen Receptor Modulators (SERMs) |
14.1.4. Biguanides |
14.1.5. Others |
14.2. Route of Administration Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%), and Market Share (%) |
14.2.1. Oral |
14.2.2. Intravenous |
14.2.3. Subcutaneous |
14.2.4. Intramuscular |
14.3. Gender Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Men |
14.3.2. Women |
14.4. Distribution Channels Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacies |
14.4.2. Retail Pharmacies |
14.4.3. Online Pharmacies |
14.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (US$ Mn) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Gulf CoDistribution Channels Council (GCC) Countries |
14.5.2. South Africa |
14.5.3. Rest of MEA |
14.6. MEA Infertility Therapeutics Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Gender, By Distribution Channels, and Country, 2022-2028 |
14.7. MEA Infertility Therapeutics Market Dynamics – Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, Key products, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. Abbott Laboratories |
15.2.2. Takeda Pharmaceutical Company Limited |
15.2.3. Ferring Pharmaceuticals Inc. |
15.2.4. Pfizer Inc. |
15.2.5. Novartis International AG |
15.2.6. Bayer AG |
15.2.7. Teva Pharmaceticals Industries |
15.2.8. Merck & Co., Inc. |
15.2.9. Vitrolife AB |
15.2.10. MedGyn Products, Inc. |
16. Research Methodology |
17. Key Assumptions and Acronyms |
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players